General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-14 | 2024-03 | 0 | -0.05 | N/A | N/A |
2024-02-14 | 2023-12 | 0 | -0.24 | N/A | N/A |
2023-11-13 | 2023-09 | 0 | -1.83 | N/A | N/A |
2023-09-18 | 2023-06 | -0.18 | -1.95 | -1.77 | -983.33% |
2023-05-11 | 2023-03 | -0.1 | -1.94 | -1.84 | -1840.00% |
2023-02-14 | 2022-12 | -2.8 | -2.1 | 0.7 | 25.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-07-13 | Maxim Group | Upgrade | Hold | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2017-10-05 | BACHA JEFFREY | Chief Executive Officer | 63.70K | Purchase |
2019-09-12 | BELL JOHN K | Director | 44.70K | Purchase |
2022-07-31 | BROWN DENNIS M | Officer | 300.65K | Stock Award(Grant) |
2023-05-31 | HOFFMAN ROBERT E | Chief Executive Officer | 68.90K | Stock Award(Grant) |
2021-11-21 | JOHNSON LAURA LAURA | Director | 3.00K | Purchase |
2020-08-18 | LIATOS JOHN | Officer and Director | 196.75K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Geode Capital Management, LLC | 14.04K | 56.57K | 0.80% |
2023-06-29 | State Street Corporation | 10.72K | 43.21K | 0.61% |
2023-06-29 | Acadian Asset Management. LLC | 6.48K | 26.11K | 0.37% |
2023-06-29 | Tower Research Capital LLC (TRC) | 4.78K | 19.25K | 0.27% |
2023-06-29 | Morgan Stanley | 3.35K | 13.48K | 0.19% |
2023-06-29 | Osaic Holdings Inc | 981.00 | 3.95K | 0.06% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-05-30 | Fidelity Extended Market Index Fund | 9.10K | 29.22K | 0.52% |
2023-06-29 | Vanguard Extended Market Index Fund | 7.56K | 30.48K | 0.43% |
2023-05-30 | Fidelity Series Total Market Index Fund | 1.86K | 5.97K | 0.11% |
2023-05-30 | Fidelity Total Market Index Fund | 1.38K | 4.43K | 0.08% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 1.22K | 3.91K | 0.07% |
Split | Date |
---|---|
1 : 50 | 2022-11-14 |
1 : 10 | 2019-05-08 |
KTRA’s drug is effective on treating a cancer that KEYTUDRA is not. KEYTUDRA is under the MRK stock ticker and trades at $125 a share as of yesterday
Why would people think there is anything but positive
Even if these share are 3% of that, it still makes these $3.75 a share Minimum
Question:
Let’s say all of the merger deal stuff is completed:
KTRA’s drug is effective on treating a cancer that KEYTUDRA is not. KEYTUDRA is under the MRK stock ticker and trades at $125 a share as of yesterday
Why would people think there is anything but positive
Even if these share are 3% of that, it still makes these $3.75 a share Minimum
I don’t want to argue but tell me where I may have gone wrong with my thinking…125,putthese at
Me personally, I would be perfectly fine losing all my money for a chance of this helping people.
I know the market should be all about money but I’ll support on the chance of changing lives
Good luck to all but I’m a believe in the future of this discovery
But I’m still going to put this money bag on my post
I think that’s false. There is news from today and when it’s released is important but I believe FOMO is what we will see based off of all the positives so far
Oh man….
They circle jerk on Saturdays and then post bullshit
Updates?
6 minutes till blast off
YOU HAVE 11 minutes to make a decision
Tomorrow will be too late
Powell
You are now FOR KTRA?
COVERING STARTING SOON
Know what you hold
Monday this will be crazy
I’m honestly not trying to pump the stock as I have said this all along…..
This is a significantly under valued stock with HUGE potential in the near future
This is an investment and not a pump and dump
ED P is a short
I remember him from every stock spewing
Let’s talk when the day ends